4.6 Article

Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats

Journal

NEURO-ONCOLOGY
Volume 16, Issue 1, Pages 21-28

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/not149

Keywords

angiogenesis; CXCL12; CXCR4; CXCR7; ENU-induced tumors; glioblastoma; irradiation; NOX-A12; SDF-1; vasculogenesis

Funding

  1. National Institutes of Health [R01CA128873, R01 CA149318]
  2. NOXXON Pharma AG

Ask authors/readers for more resources

Tumor irradiation blocks local angiogenesis, forcing any recurrent tumor to form new vessels from circulating cells. We have previously demonstrated that the post-irradiation recurrence of human glioblastomas in the brains of nude mice can be delayed or prevented by inhibiting circulating blood vesselforming cells by blocking the interaction of CXCR4 with its ligand stromal cell-derived factor (SDF)1 (CXCL12). In the present study we test this strategy by directly neutralizing SDF-1 in a clinically relevant model using autochthonous brain tumors in immune competent hosts. We used NOX-A12, an l-enantiomeric RNA oligonucleotide that binds and inhibits SDF-1 with high affinity. We tested the effect of this inhibitor on the response to irradiation of brain tumors in rat induced by n-ethyl-N-nitrosourea. Rats treated in utero with N-ethyl-N-nitrosourea began to die of brain tumors from approximately 120 days of age. We delivered a single dose of whole brain irradiation (20 Gy) on day 115 of age, began treatment with NOX-A12 immediately following irradiation, and continued with either 5 or 20 mg/kg for 4 or 8 weeks, doses and times equivalent to well-tolerated human exposures. We found a marked prolongation of rat life span that was dependent on both drug dose and duration of treatment. In addition we treated tumors only when they were visible by MRI and demonstrated complete regression of the tumors that was not achieved by irradiation alone or with the addition of temozolomide. Inhibition of SDF-1 following tumor irradiation is a powerful way of improving tumor response of glioblastoma multiforme.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available